Pneumococcal Disease: Global Disease Prevention Strategies with a Focus on the Challenges in Iraq

References

• Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Available from: https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html. Accessed May 18, 2023.
   Google Scholar
• World Health Organization. Pneumococcal Disease. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease. Accessed March 1, 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease: global pneumococcal disease and vaccination. Available from: https://www.cdc.gov/pneumococcal/global.html. Accessed May 18, 2023.
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–e757. doi:10.1016/S2214-109X(18)30247-X
   PubMed Web of Science ®Google Scholar
• VIEW-hub. International Vaccine Access Center [IVAC], Johns Hopkins Bloomberg school of public health. Available from: https://view-hub.org/. Accessed May 18, 2023.
   Google Scholar
• Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–899. doi:10.1128/CMR.00024-15
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657. doi:10.1371/journal.pmed.1001657
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51. doi:10.1111/1469-0691.12461
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper–February 2019. Weekly Epidemiological Record. 2019;94(08):85–104.
   Google Scholar
• Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia. Med Clin North Am. 2019;103(3):487–501. doi:10.1016/j.mcna.2018.12.008
   PubMed Web of Science ®Google Scholar
• Bentley SD, Aanensen DM, Mavroidi A, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2006;2(3):e31. doi:10.1371/journal.pgen.0020031
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348. doi:10.1371/journal.pmed.1000348
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease: risk factors. Available from: https://www.cdc.gov/pneumococcal/clinicians/risk-factors.html. Accessed May 18, 2023.
   Google Scholar
• Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984–989. doi:10.1136/thoraxjnl-2015-206780
   PubMed Web of Science ®Google Scholar
• Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci U S A. 2018;115(51):12896–12901. doi:10.1073/pnas.1721095115
   PubMed Web of Science ®Google Scholar
• Hilleman MR, Carlson AJ, McLean AA, Vella PP, Weibel RE, Woodhour AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis. 1981;3(Suppl):S31–S42. doi:10.1093/clinids/3.supplement_1.s31
   PubMedGoogle Scholar
• U.S. Food & Drug Administration. PNEUMOVAX 23 - pneumococcal vaccine, polyvalent. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/pneumovax-23-pneumococcal-vaccine-polyvalent. Accessed May 18, 2023.
   Google Scholar
• Zangeneh TT, Baracco G, Al-Tawfiq JA. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Expert Rev Vaccines. 2011;10(3):345–353. doi:10.1586/erv.11.1
   PubMed Web of Science ®Google Scholar
• Lecrenier N, Marijam A, Olbrecht J, Soumahoro L, Nieto Guevara J, Mungall B. Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children. Expert Rev Vaccines. 2020;19(3):247–265. doi:10.1080/14760584.2020.1738226
   PubMed Web of Science ®Google Scholar
• Serum Institute of India Pvt. Ltd. Pneumococcal polysaccharide conjugate vaccine (adsorbed) pneumosil (10-valent). Available from: https://www.seruminstitute.com/product_ind_pneumosil.php. Accessed May 18, 2023.
   Google Scholar
• U.S. Food & Drug Administration. Prevnar 13. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-13. Accessed March 24, 2022.
   Google Scholar
• U.S. Food & Drug Administration. Vaxneuvance. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance. Accessed May 18, 2023.
   Google Scholar
• U.S. Food & Drug Administration. Prevnar 20. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20. Accessed May 18, 2023.
   Google Scholar
• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144–154. doi:10.1016/S1473-3099(04)00938-7
   PubMed Web of Science ®Google Scholar
• Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–367. doi:10.1038/s41579-018-0001-8
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Nohynek H. World Health Organization pneumococcal vaccine trials carriage working G. Report from a WHO working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003;22(2):e1–e11. doi:10.1097/01.inf.0000049347.42983.77
   PubMed Web of Science ®Google Scholar
• Haraldsson A. Vaccine implementation reduces inequity. Lancet Glob Health. 2018;6(12):e1264–e1265. doi:10.1016/S2214-109X(18)30489-3
   PubMed Web of Science ®Google Scholar
• Neal EFG, Nguyen CD, Ratu FT, et al. Factors associated with pneumococcal carriage and density in children and adults in Fiji, using four cross-sectional surveys. PLoS One. 2020;15(4):e0231041. doi:10.1371/journal.pone.0231041
   PubMed Web of Science ®Google Scholar
• Chan J, Nguyen CD, Dunne EM, et al. Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries. Vaccine. 2019;37(43):6299–6309. doi:10.1016/j.vaccine.2019.08.073
   PubMed Web of Science ®Google Scholar
• Brooks LRK, Mias GI. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol. 2018;9:1366. doi:10.3389/fimmu.2018.01366
   PubMed Web of Science ®Google Scholar
• Al-Sanouri T, Mahdi S, Khader IA, et al. The epidemiology of meningococcal meningitis: multicenter, hospital-based surveillance of meningococcal meningitis in Iraq. IJID Regions. 2021;1:100–106. doi:10.1016/j.ijregi.2021.10.006
   PubMedGoogle Scholar
• Al-Ansari F, Mirzaei M, Al-Ansari B, et al. Health risks, preventive behaviours and respiratory illnesses at the 2019 Arbaeen: implications for COVID-19 and other pandemics. Int J Environ Res Public Health. 2021;18(6):3287. doi:10.3390/ijerph18063287
   PubMed Web of Science ®Google Scholar
• World Health Organization. The top 10 causes of death. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed May 18, 2023.
   Google Scholar
• World Health Organization. Children: improving survival and well-being. Available from: https://www.who.int/news-room/fact-sheets/detail/children-reducing-mortality. Accessed May 18, 2023.
   Google Scholar
• World Health Organization. Pneumonia. Available from: https://www.who.int/health-topics/pneumonia#tab=tab_1. Accessed March 21, 2022.
   Google Scholar
• G. B. D lower respiratory infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–1210. doi:10.1016/S1473-3099(18)30310-4
   PubMed Web of Science ®Google Scholar
• Dagan R, Bhutta ZA, de Quadros CA, et al. The remaining challenge of pneumonia: the leading killer of children. Pediatr Infect Dis J. 2011;30(1):1–2. doi:10.1097/INF.0b013e3182005389
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197–209. doi:10.1016/j.ijid.2009.05.010
   PubMed Web of Science ®Google Scholar
• Roca A, Sigauque B, Quinto L, et al. Invasive pneumococcal disease in children<5 years of age in rural Mozambique. Trop Med Int Health. 2006;11(9):1422–1431. doi:10.1111/j.1365-3156.2006.01697.x
   PubMed Web of Science ®Google Scholar
• Farooqui H, Jit M, Heymann DL, Zodpey S. Burden of severe pneumonia, pneumococcal pneumonia and pneumonia deaths in Indian States: modelling based estimates. PLoS One. 2015;10(6):e0129191. doi:10.1371/journal.pone.0129191
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease: fast facts you need to know about pneumococcal disease. Available from: https://www.cdc.gov/pneumococcal/about/facts.html. Accessed May 18, 2023.
   Google Scholar
• Ferreira-Coimbra J, Sarda C, Rello J. Burden of community-acquired pneumonia and unmet clinical needs. Adv Ther. 2020;37(4):1302–1318. doi:10.1007/s12325-020-01248-7
   PubMed Web of Science ®Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–3412. doi:10.1016/j.vaccine.2011.02.088
   PubMed Web of Science ®Google Scholar
• Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589–1592. doi:10.1093/infdis/jis240
   PubMed Web of Science ®Google Scholar
• Brown JD, Harnett J, Chambers R, Sato R. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr. 2018;18(1):92. doi:10.1186/s12877-018-0787-2
   PubMed Web of Science ®Google Scholar
• Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia. PLoS One. 2013;8(8):e71375. doi:10.1371/journal.pone.0071375
   PubMed Web of Science ®Google Scholar
• Al Dallal SAM, Farghaly M, Ghorab A, et al. Real-world evaluation of costs of illness for pneumonia in adult patients in Dubai-A claims database study. PLoS One. 2021;16(9):e0256856. doi:10.1371/journal.pone.0256856
   PubMed Web of Science ®Google Scholar
• Schuchat A. Pneumococcal Prevention Gets Older and Wiser. JAMA Intern Med. 2015;175(12):1897–1898. doi:10.1001/jamainternmed.2015.6133
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global market study, Pneumococcal Conjugate (PCV) and Polysaccharide (PPV) vaccines; 2020:6. Available from: https://www.who.int/immunization/programmes_systems/procurement/mi4a/platform/module2/Pneumococcal_Vaccine_Market_Study-June2020.pdf. Accessed 17, March, 2022.
   Google Scholar
• Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992;165(Suppl 1):S49–S52. doi:10.1093/infdis/165-supplement_1-s49
   PubMedGoogle Scholar
• Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008;32(3):199–206. doi:10.1016/j.ijantimicag.2008.01.021
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998–2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144–148.
   PubMedGoogle Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Expert Rev Vaccines. 2009;8(11):1479–1500. doi:10.1586/erv.09.113
   PubMed Web of Science ®Google Scholar
• Rodgers GL, Whitney CG, Klugman KP. Triumph of pneumococcal conjugate vaccines: overcoming a common foe. J Infect Dis. 2021;224(12 Suppl 2):S352–S359. doi:10.1093/infdis/jiaa535
   PubMedGoogle Scholar
• Alderson MR, Sethna V, Newhouse LC, Lamola S, Dhere R. Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL(R)). Hum Vaccin Immunother. 2021;17(8):2670–2677. doi:10.1080/21645515.2021.1874219
   PubMed Web of Science ®Google Scholar
• World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring; 2014:924150689X. Available from: https://apps.who.int/iris/handle/10665/111548. Accessed May 18, 2023.
   Google Scholar
• World Health Organization. Considerations for pneumococcal vaccination in older adults. Weekly Epidemiological Record. 2021;23(11):217–228.
   Google Scholar
• Vaccine Knowledge Project. PCV (Pneumococcal Conjugate Vaccine). Available from: https://vk.ovg.ox.ac.uk/vk/pcv. Accessed May 18, 2023.
   Google Scholar
• Edouard S, Al-Tawfiq JA, Memish ZA, Yezli S, Gautret P. Impact of the Hajj on pneumococcal carriage and the effect of various pneumococcal vaccines. Vaccine. 2018;36(48):7415–7422. doi:10.1016/j.vaccine.2018.09.017
   PubMed Web of Science ®Google Scholar
• Memish ZA, Assiri A, Almasri M, et al. Impact of the Hajj on pneumococcal transmission. Clin Microbiol Infect. 2015;21(1):e77–e111. doi:10.1016/j.cmi.2014.07.005
   PubMed Web of Science ®Google Scholar
• Alharbi NS, Al-Barrak AM, Al-Moamary MS, et al. The Saudi Thoracic Society pneumococcal vaccination guidelines-2016. Ann Thorac Med. 2016;11(2):93–102. doi:10.4103/1817-1737.177470
   PubMed Web of Science ®Google Scholar
• Muhoza P, Danovaro-Holliday MC, Diallo MS, et al. Routine vaccination coverage - worldwide, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(43):1495–1500. doi:10.15585/mmwr.mm7043a1
   PubMed Web of Science ®Google Scholar
• Lu PJ, Hung MC, Srivastav A, et al. Surveillance of vaccination coverage among adult populations -United States, 2018. MMWR Surveill Summ. 2021;70(3):1–26. doi:10.15585/mmwr.ss7003a1
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2020 to March 2021; 2021:14. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1035189/hpr1921-ppv-vc.pdf. Accessed May 18, 2023.
   Google Scholar
• Chapman R, Sutton K, Dillon-Murphy D, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis. Vaccine. 2020;38(45):7138–7145. doi:10.1016/j.vaccine.2020.08.068
   PubMed Web of Science ®Google Scholar
• Megiddo I, Klein E, Laxminarayan R. Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India. BMJ Glob Health. 2018;3(3):e000636. doi:10.1136/bmjgh-2017-000636
   PubMed Web of Science ®Google Scholar
• Haridy H, Wasserman M. PIN95 public health IMPACT of 10 YEARS of the 13 valent pneumococcal vaccine in Africa and the middle east in children UNDER 5 YEARS. Value Health. 2020;23:S560. doi:10.1016/j.jval.2020.08.936
   Web of Science ®Google Scholar
• Glikman D, Dagan R, Barkai G, et al. Dynamics of severe and non-severe invasive pneumococcal disease in young children in Israel following PCV7/PCV13 introduction. Pediatr Infect Dis J. 2018;37(10):1048–1053. doi:10.1097/INF.0000000000002100
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal vaccination: what everyone should know. Available from: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html#:~:text=The%20United%20States%20saw%20largeActive%20Bacterial%20Core%20surveillance%20data. Accessed March 1, 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease: surveillance and reporting. Available from: https://www.cdc.gov/pneumococcal/surveillance.html. Accessed March 1, 2022.
   Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155–163. doi:10.1056/NEJMoa1209165
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. National laboratory surveillance of invasive streptococcal disease in Canada-annual summary 2018; 2018. Available from: https://publications.gc.ca/collections/collection_2021/aspc-phac/HP57-4-2018-eng.pdf. Accessed 17, March 2022.
   Google Scholar
• De Wals P, Lefebvre B, Markowski F, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2014;32(13):1501–1506. doi:10.1016/j.vaccine.2013.11.028
   PubMed Web of Science ®Google Scholar
• De Wals P, Lefebvre B, Deceuninck G, Longtin J. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. Vaccine. 2018;36(3):421–426. doi:10.1016/j.vaccine.2017.11.054
   PubMed Web of Science ®Google Scholar
• Caroline Q. Vaccination against pneumococcal infection in Canada. Педиатрическая фармакология. 2014;11(1):16.
   Google Scholar
• UK Department of Health. Pneumococcal: the green book of immunisation, chapter 25; 2020:1–13. Available from: https://www.gov.uk/government/publications/pneumococcal-The-green-book-chapter-25. Accessed March 20, 2022.
   Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768. doi:10.1016/S1473-3099(11)70090-1
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543. doi:10.1016/S1473-3099(15)70044-7
   PubMed Web of Science ®Google Scholar
• The World Bank. Iraq. Available from: https://data.worldbank.org/country/IQ. Accessed May 18, 2023.
   Google Scholar
• The World Bank. Population ages 65 and above (% of total population) – Iraq. Available from: https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=IQ. Accessed May 18, 2023.
   Google Scholar
• World Health Organization. Noncommunicable diseases country profiles 2018; 2018:224. Available from: https://www.who.int/publications/i/item/9789241514620. Accessed May 18, 2023.
   Google Scholar
• Ibrahim BA, Al-Humaish S, Al-Obaide MAI. Tobacco smoking, lung cancer, and therapy in Iraq: current perspective. Front Public Health. 2018;6:311. doi:10.3389/fpubh.2018.00311
   PubMed Web of Science ®Google Scholar
• Rehm SJ, File TM, Metersky M, Nichol KL, Schaffner W. National Foundation for Infectious Diseases Pneumococcal Disease Advisory B. Identifying barriers to adult pneumococcal vaccination: an NFID task force meeting. Postgrad Med. 2012;124(3):71–79. doi:10.3810/pgm.2012.05.2550
   PubMed Web of Science ®Google Scholar
• Abdulah DM. Prevalence and correlates of COVID-19 vaccine hesitancy in the general public in Iraqi Kurdistan: a cross-sectional study. J Med Virol. 2021;93(12):6722–6731. doi:10.1002/jmv.27255
   PubMed Web of Science ®Google Scholar
• Care Evaluations. COVID-19 vaccination uptake: a study of knowledge, attitudes and practices of marginalized communities in Iraq; 2021. Available from: http://careevaluations.org/evaluation/covid-19-vaccination-uptake-A-study-of-knowledge-attitudes-and-practices-of-marginalized-communities-in-iraq/. Accessed May 18, 2023.
   Google Scholar
• Luma AH, Haveen AH, Faiq BB, Stefania M, Leonardo EG. Hesitancy towards Covid-19 vaccination among the healthcare workers in Iraqi Kurdistan. Public Health Pract. 2022;3:100222. doi:10.1016/j.puhip.2021.100222
   Google Scholar
• United States Agency for International Development. National immunization plan of Iraq for 2015; 2014. Available from: https://pdf.usaid.gov/pdf_docs/PA00KD56.pdf. Accessed May 18, 2023.
   Google Scholar
• Lafta R, Hussain A. Trend of vaccine preventable diseases in Iraq in time of conflict. Pan Afr Med J. 2018;31:130. doi:10.11604/pamj.2018.31.130.16394
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization coverage. Available from: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage. Accessed May 18, 2023.
   Google Scholar
• Chen C, Cervero Liceras F, Flasche S, et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 2019;7(1):e58–e67. doi:10.1016/S2214-109X(18)30422-4
   PubMed Web of Science ®Google Scholar
• Hossain SMM, Hilfi RA, Rahi A, et al. Annual cost savings of US$70 million with similar outcomes: vaccine procurement experience from Iraq. BMJ Glob Health. 2022;7(2):e008005. doi:10.1136/bmjgh-2021-008005
   PubMed Web of Science ®Google Scholar
• Berkley S. Vaccination lags behind in middle-income countries. Nature. 2019;569(7756):309. doi:10.1038/d41586-019-01494-y
   PubMed Web of Science ®Google Scholar
• Kuehne F, Sanftenberg L, Dreischulte T, Gensichen J. Shared decision making enhances pneumococcal vaccination rates in adult patients in outpatient care. Int J Environ Res Public Health. 2020;17(23):9146. doi:10.3390/ijerph17239146
   PubMed Web of Science ®Google Scholar
• Chaiyakunapruk N, Somkrua R, Hutubessy R, et al. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Med. 2011;9:53. doi:10.1186/1741-7015-9-53
   PubMed Web of Science ®Google Scholar
• UNICEF. Assessment of COVID-19 Impact on Poverty and Vulnerability in Iraq; 2020.
   Google Scholar
• Pfizer. positive top-line results of pfizer’s phase 3 study exploring coadministration of PREVNAR 20™ with Pfizer-BioNTech COVID-19 vaccine in older adults released. Available from: https://www.pfizer.com/news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring-0. Accessed May 18, 2023.
   Google Scholar
• Sultana J, Mazzaglia G, Luxi N, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Rev Vaccines. 2020;19(10):919–936. doi:10.1080/14760584.2020.1825951
   PubMed Web of Science ®Google Scholar